Echocardiography is the predominant imaging method used for patients with aortic valve disease because of its excellent diagnostic accuracy, high reproducibility and noninvasive nature. Cardiac catheterization is typically reserved for patients in whom the diagnosis remains unclear, those requiring coronary angiography prior to valve replacement, and in the setting of complex valve disease. Cardiac computed tomography (CT) has recently been applied as a research tool to quantify the amount of aortic valve calcium (AVC), which has served as a clinical end point in several medical therapy trials.
Medical therapy for aortic valve disease remains an active area of clinical research. Multiple retrospective studies have shown a benefit for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins) in reducing disease progression. However, two recently completed prospective, randomized trials yielded conflicting results. The data for using angiotensin converting enzyme (ACE) inhibitors are in the preliminary stages. This review will focus on imaging methods that are available for patients with aortic valve disease and summarize the recent trials that have evaluated medical therapy aimed to reduce progression of aortic valve disease.
GorlinR, GorlinSG.Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I Am Heart J1951;41:1–29.
2.
CurriePJ, SewardJB, ReederGS, . Continuous-wave Doppler echocardiographic assessment of severity of calcific aortic stenosis: a simultaneous Doppler-catheter correlative study in 100 adult patients. Circulation1985;71:1162–9.
3.
ShavelleDM, OttoCM.Aortic stenosis. In:OttoCM, editor. The practice of clinical echocardiography. Philadelphia, PA: W.B. Saunders Company; 2002. p.469–500.
4.
OttoCM, BurwashIG, LeggetME, . Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation1997;95:2262–70.
5.
KizerJR, GefterWB, deLemosAS, . Electron beam computed tomography for the quantification of aortic valvular calcification. J Heart Valve Dis2001;10:361–6.
6.
BudoffMJ, TakasuJ, KatzR, . Reproducibility of CT measurements of aortic valve calcification, mitral annulus calcification, and aortic wall calcification in the multi-ethnic study of atherosclerosis. Acad Radiol2006;13:166–72.
7.
Messika-ZeitounD, AubryMC, DetaintD, . Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation2004;110:356–62.
8.
ShavelleDM, BudoffMJ, BuljubasicN, . Usefulness of aortic valve calcium scores by electron beam computed tomography as a marker for aortic stenosis. Am J Cardiol2003;92:349–53.
9.
RosenhekR, BinderT, PorentaG, . Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med2000;343:611–7.
10.
O'BrienKD.Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol2006;26:1721–8.
11.
OttoCM, KuusistoJ, ReichenbachDD, . Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation1994;90:844–53.
12.
O'BrienKD,ReichenbachDD, MarcovinaSM, . Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol1996;16:523–32.
13.
MohlerERIII, AdamLP, McClellandP, . Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol1997;17:547–52.
14.
O'BrienKD, ShavelleDM, CaulfieldMT, . Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation2002;106:2224–30.
15.
StewartBF, SiscovickD, LindBK, . Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study J Am Coll Cardiol1997;29:630–4.
16.
RajamannanNM, SubramaniamM, SpringettM, . Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation2002;105:2660–5.
17.
Antonini-CanterinF, PopescuBA, HuangG, . Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment?Ital Heart J2005;6:119–24.
18.
CowellSJ, NewbyDE, PrescottRJ, . A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med2005;352:2389–97.
19.
MouraLM, RamosSF, ZamoranoJL, . Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol2007;49:554–61.
20.
RosseboAB, PedersenTR, AllenC, . Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol2007;99:970–3.
21.
ShavelleDM.Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis?Heart2005;91:1257–9.
22.
O'BrienKD, ZhaoXQ, ShavelleDM, . Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med2004;52:185–91.
23.
ChockalingamA, VenkatesanS, SubramaniamT, . Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J2004;147:E19.
24.
Jimenez-CandilJ, BermejoJ, YottiR, . Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart2005;91:1311–8.
25.
MartinezSC, HenneO, ArceoA, . [Hemodynamic effects of oral captopril in patients with critical aortic stenosis]. Arch Inst Cardiol Mex1996;66:322–30.
26.
O'BrienKD, ProbstfieldJL, CaulfieldMT, . Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med2005;165:858–62.
27.
RosenhekR, RaderF, LohoN, . Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation2004;110:1291–5.
28.
ShareghiS, RasouliL, ShavelleDM, . Current results of balloon aortic valvuloplasty in high-risk patients. J Invasive Cardiol2007;19:1–5.
29.
CribierA, EltchaninoffH, BashA, . Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation2002;106:3006–8.
30.
LeonMB, KodaliS, WilliamsM, . Transcatheter aortic valve replacement in patients with critical aortic stenosis: rationale, device descriptions, early clinical experiences, and perspectives. Semin Thorac Cardiovasc Surg2006;18:165–74.
31.
ShavelleDM, TakasuJ, BudoffMJ, . HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet2002;359:1125–6.
32.
AronowWS, AhnC, KronzonI, GoldmanME.Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol2001;88:693–5.
33.
PohleK, MaffertR, RopersD, . Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation2001;104:1927–32.
34.
NovaroGM, TiongIY, PearceGL, . Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation2001;104:2205–9.
35.
BellamyMF, PellikkaPA, KlarichKW, . Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosisin the community. J Am Coll Cardiol2002;40:1723–30.
